ClinicalTrials.gg

Program

Pegloticase

Also written as “pegloticase”, “Pegloticase with MTX” and “Puricase”.

Its studies are mostly in Gout · Renal Insufficiency, Chronic, led by 3 companies.

Furthest: phase 4, since Aug 9, 201814 company-led studies, 1 open or runningNext primary completion: Jun 18, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen81 open or runningphase 4since Aug 9, 2018Aug 9, 2018Jun 18, 2028phase 3 · NCT07388498
Savient Pharmaceuticals50 open or runningphase 3since May 10, 2006Mar 24, 2004none ahead
Ampel BioSolutions10 open or runningphase 2since Oct 30, 2015Oct 30, 2015none ahead

Also a collaborator on its studies: ind-2-results-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2004First study: phase 2 study in GoutNew to Savient PharmaceuticalsSavient Pharmaceuticals · NCT00080210 · 40 enrolled · United States
  2. May 10, 2006Phase 3 study in GoutSavient Pharmaceuticals · NCT00325195 · 225 enrolled · United States, Canada, Mexico
  3. May 6, 2008Phase 3 study in GoutSavient Pharmaceuticals · NCT00675103 · 7 enrolled · United States
  4. Oct 27, 2008Phase 3 study in GoutSavient Pharmaceuticals · NCT01356498 · 151 enrolled · United States
  5. Nov 29, 2012Phase 1 study in Renal Insufficiency, ChronicSavient Pharmaceuticals · NCT01739660 · 12 enrolled · United States
  6. Oct 30, 2015Ampel BioSolutions's first study: phase 2 study in GoutNew to Ampel BioSolutionsAmpel BioSolutions · NCT02598596 · 132 enrolled · United States
  7. Aug 9, 2018Amgen's first study: phase 4 study in GoutNew to AmgenAmgen · NCT03635957 · 14 enrolled · United States
  8. Jun 19, 2019Phase 4 study in GoutAmgen · NCT03994731 · 152 enrolled · United States
  9. Sep 11, 2019Phase 4 study in Uncontrolled GoutAmgen · NCT04087720 · 20 enrolled · United States
  10. Aug 11, 2020Phase 4 study in GoutAmgen · NCT04511702 · 191 enrolled · United States
  11. Feb 12, 20212 phase 4 studies in GoutAmgen · NCT04762498, NCT04772313
  12. Jan 19, 2024Phase 4 study in GoutAmgen · NCT06229145 · 306 enrolled · United States
  13. Jan 29, 2026Phase 3 study in Uncontrolled GoutAmgen · NCT07388498 · 270 planned · United States, Puerto Rico

Ahead

  1. Jun 18, 2028Primary completion: phase 3 study in Uncontrolled GoutAmgen · NCT07388498

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07388498Uncontrolled Gout · United States, Puerto Rico3RecruitingAmgenJun 18, 2028270
NCT06229145Gout · United States4CompletedAmgenJul 30, 2025306
NCT04772313Gout · United States4CompletedAmgenAug 23, 202211
NCT04762498Gout · United States4CompletedAmgenMay 18, 202354
NCT04511702Gout · United States4CompletedAmgenJan 18, 2024191
NCT04087720Uncontrolled Gout · United States4CompletedAmgenJul 6, 202120
NCT03994731Gout · United States4CompletedAmgenMar 17, 2021152
NCT03635957Gout · United States4CompletedAmgenOct 23, 201914
NCT02598596Gout · United States2CompletedAmpel BioSolutionsApr 13, 2020132
NCT01739660Renal Insufficiency, Chronic · United States1CompletedSavient PharmaceuticalsApr 201312
NCT01356498Gout · United States3CompletedSavient PharmaceuticalsJan 2010151
NCT00675103Gout · United States3CompletedSavient PharmaceuticalsJan 20097
NCT00325195Gout · United States, Canada, Mexico3CompletedSavient PharmaceuticalsOct 2007225
NCT00080210Gout · United States2CompletedSavient Pharmaceuticals40

How it is read

Names in the registry

  • “Pegloticase”, 9 entries
  • “pegloticase”, 2 entries
  • “Pegloticase with MTX”, 1 entry
  • “Puricase”, 1 entry
  • “pegloticase 8 mg i.v.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.